What is the appropriate treatment for acute bacterial sinusitis in a patient with a penicillin allergy?

Treatment of Acute Bacterial Sinusitis in Patients with Penicillin Allergy

For patients with penicillin allergy and acute bacterial sinusitis, use a respiratory fluoroquinolone (levofloxacin 500 mg once daily for 10–14 days or moxifloxacin 400 mg once daily for 10 days) if the allergy is severe (anaphylaxis, urticaria, angioedema), or use a second- or third-generation cephalosporin (cefuroxime, cefpodoxime, cefdinir) for 10 days if the allergy is non-severe (mild rash). 1, 2

---

Step 1: Classify the Type of Penicillin Allergy

The first critical step is determining whether the patient has a Type I (IgE-mediated/anaphylactic) versus a non-Type I (delayed, mild rash) penicillin allergy, because this dictates antibiotic selection. 1, 2

• Type I (severe) allergy: History of anaphylaxis, urticaria, angioedema, or bronchospasm after penicillin exposure. 1, 2
• Non-Type I (mild) allergy: History of delayed rash, mild gastrointestinal upset, or other non-IgE-mediated reactions. 1, 2

---

Step 2: Confirm the Diagnosis of Acute Bacterial Sinusitis

Before prescribing antibiotics, confirm that the patient meets at least one of the following criteria for acute bacterial rhinosinusitis (ABRS), because 98–99.5% of acute sinusitis is viral and resolves without antibiotics within 7–10 days: 1

• Persistent symptoms ≥10 days without improvement (purulent nasal discharge plus nasal obstruction or facial pain/pressure). 1, 3
• Severe symptoms ≥3–4 consecutive days with fever ≥39°C, purulent nasal discharge, and facial pain. 1, 3
• "Double sickening": Initial improvement from a viral URI followed by worsening symptoms within 10 days. 1, 3

Do not prescribe antibiotics for symptoms lasting <10 days unless severe features are present. 1

---

Step 3: Select the Appropriate Antibiotic Based on Allergy Type

For Non-Severe (Non-Type I) Penicillin Allergy:

Use a second- or third-generation cephalosporin for 10 days, because cross-reactivity with penicillin is negligible (<1%) and these agents provide excellent coverage against the three major sinusitis pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis). 1, 2, 4

Preferred options include:

• Cefuroxime axetil 250–500 mg twice daily for 10 days. 1, 2, 4
• Cefpodoxime proxetil 200 mg twice daily for 10 days. 1, 2, 4
• Cefdinir 300 mg twice daily for 10 days. 1, 2, 4
• Cefprozil is another acceptable option. 1, 2

These cephalosporins are unlikely to cause cross-reactivity in patients with non-severe penicillin allergy and are recommended as first-line alternatives by multiple guidelines. 1, 2, 4

---

For Severe (Type I/Anaphylactic) Penicillin Allergy:

Use a respiratory fluoroquinolone, because cephalosporins carry a 1–10% cross-reactivity risk with Type I penicillin allergy and should be avoided. 1, 2

Preferred options include:

• Levofloxacin 500 mg once daily for 10–14 days. 1, 2, 5
• Moxifloxacin 400 mg once daily for 10 days. 1, 2

Respiratory fluoroquinolones provide 90–92% predicted clinical efficacy against all major sinusitis pathogens, including multidrug-resistant S. pneumoniae (MDRSP) and β-lactamase-producing H. influenzae and M. catarrhalis. 1, 2, 5

---

Step 4: Avoid Inappropriate Antibiotics

The following antibiotics should NOT be used as first-line therapy for acute bacterial sinusitis in penicillin-allergic patients due to high resistance rates or inadequate coverage: 1, 6

• Azithromycin and other macrolides: Resistance rates exceed 20–25% for both S. pneumoniae and H. influenzae, making treatment failure likely. 1, 6, 7
• Trimethoprim-sulfamethoxazole (Bactrim): Resistance rates reach 50% for S. pneumoniae and 27% for H. influenzae. 1, 6
• First-generation cephalosporins (e.g., cephalexin): Inadequate coverage against H. influenzae because approximately 50% of strains produce β-lactamase. 1
• Clindamycin monotherapy: Lacks activity against H. influenzae and M. catarrhalis, leading to 30–40% failure rates. 1, 6

---

Step 5: Add Essential Adjunctive Therapies to All Patients

Adjunctive therapies significantly improve symptom resolution and should be added to antibiotic therapy in all patients: 1

• Intranasal corticosteroids (mometasone, fluticasone, or budesonide) twice daily reduce mucosal inflammation and accelerate recovery; supported by strong evidence from multiple randomized controlled trials. 1, 2
• Saline nasal irrigation 2–3 times daily provides symptomatic relief and helps clear purulent secretions. 1, 2
• Analgesics (acetaminophen or ibuprofen) for pain and fever control. 1, 2

---

Step 6: Monitor Response and Reassess

Reassessment at specific timepoints is critical to identify treatment failure early and prevent complications: 1

• Reassess at 3–5 days: If no clinical improvement (persistent purulent drainage, unchanged facial pain, or worsening), switch to a different antibiotic class immediately. 1

  • For patients on cephalosporins, switch to a respiratory fluoroquinolone. 1
  • For patients on fluoroquinolones, consider high-dose amoxicillin-clavulanate if the allergy permits, or re-evaluate the diagnosis. 1

• Reassess at 7 days: If symptoms persist or worsen, reconfirm the diagnosis, exclude complications (orbital cellulitis, meningitis, intracranial abscess), and consider imaging (CT scan) or ENT referral. 1

Expected timeline for improvement: Most patients should show noticeable improvement within 3–5 days of appropriate antibiotic therapy, with complete resolution by 10–14 days. 1

---

Step 7: When to Refer to Otolaryngology

Refer immediately if any of the following occur: 1, 2

• No improvement after 7 days of appropriate second-line antibiotic therapy. 1
• Worsening symptoms at any point during treatment (increasing pain, fever, purulent drainage). 1
• Signs of complications: severe headache, visual changes, periorbital swelling/erythema, proptosis, diplopia, altered mental status, or cranial nerve deficits. 1
• Recurrent sinusitis (≥3 episodes per year) requiring evaluation for underlying allergic rhinitis, immunodeficiency, or anatomic abnormalities. 1

---

Common Pitfalls to Avoid

• Do not use cephalosporins in patients with a history of anaphylaxis to penicillin without confirming the allergy type, because cross-reactivity risk is 1–10% in Type I allergy. 1, 2
• Do not prescribe macrolides (azithromycin) as first-line therapy due to high resistance rates (>20–25%), which make treatment failure likely. 1, 6, 7
• Do not use fluoroquinolones as first-line therapy in patients with non-severe penicillin allergy, because cephalosporins are equally effective and preserve fluoroquinolones for resistant infections. 1, 2
• Ensure adequate treatment duration (minimum 10 days for cephalosporins, 10–14 days for fluoroquinolones) to prevent relapse. 1, 2
• Do not delay reassessment beyond 3–5 days in non-responders, because early identification of treatment failure prevents complications. 1